| Revista: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000453062 |
| ISSN: | 0034-8376 |
| Autores: | Hamidi Alamdari, Daryoush1 Hafizi Lotfabadi, Saied2 Bagheri Moghaddam, Ahmad3 Safari, Hossin4 Mozdourian, Mahnaz5 Javidarabshahi, Zahra5 Peivandi Yazdi, Arash5 Ali Zeraati, Abass6 Sedaghat, Alireza5 Poursadegh, Farid5 Barazandeh Ahmadabadi, Fatemeh2 Agheli Rad, Marzieh2 Tavousi, Seyed M6 Vojouhi, Shohreh7 Amini, Shahram8 Amini, Mahnaz5 Majid Hosseini, Seyed9 Tavanaee Sani, Ashraf10 Ghiabi, Amin11 Nabavi Mahalli, Shima9 Morovatdar, Negar12 Rajabi, Omid13 Koliakos, George14 |
| Instituciones: | 1Surgical Oncology Research Center, Mashhad. Irán 2Shariati Hospital, Department of Internal Medicine, Teherán. Irán 3Faculty of Medicine, Department of Anesthesiology, Mashhad. Irán 4Hasheminejad Hospital, Infectious Diseases Ward, Mashhad. Irán 5Lung Diseases Research Center, Mashhad. Irán 6Faculty of Medicine, Kidney Transplantation Complications Research Center, Mashhad. Irán 7School of Medicine, Metabolic Syndrome Research Center, Mashhad. Irán 8Faculty of Medicine, Critical Care Lung Research Center, Mashhad. Irán 9Emamreza Hospital, Department of Internal Medicine, Mashhad. Irán 10Emamreza Hospital, Department of Infectious diseases, Mashhad. Irán 11Ghaem Hospital, Department of Internal Medicine, Karaj. Irán 12Imam Reza Hospital, Clinical Research Development Unit, Mashhad. Irán 13Mashhad University of Medical Sciences, School of Pharmacy, Mashhad. Irán 14Aristotle University of Thessaloniki, Medical School, Thessaloniki, Macedonia. Grecia |
| Año: | 2021 |
| Periodo: | May-Jun |
| Volumen: | 73 |
| Número: | 3 |
| Paginación: | 190-198 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental, aplicado |
| Resumen en inglés | Background: There is no pharmacological intervention on the treatment of hypoxemia and respiratory distress in COVID-19 patients. Objective: The objective of the study was to study the effect of the reduced form of methylene blue (MB) on the improvement of oxygen saturation (SpO2) and respiratory rate (RR). Methods: In an academic medical center, 80 hospitalized patients with severe COVID-19 were randomly assigned to receive either oral MB along with standard of care (SOC) (MB group, n = 40) or SOC only (SOC group, n=40). The primary outcomes were SpO2 and RR on the 3rd and 5th days. The secondary outcomes were hospital stay and mortality within 28 days. Results: In the MB group, a significant improvement in SpO2 and RR was observed on the 3rd day (for both, p < 0.0001) and also the 5th day (for both, p < 0.0001). In the SOC group, there was no significant improvement in SpO2 (p = 0.24) and RR (p = 0.20) on the 3rd day, although there was a significant improvement of SpO2 (p = 0.002) and RR (p = 0.01) on the 5th day. In the MB group in comparison to the SOC group, the rate ratio of increased SpO2 was 13.5 and 2.1 times on the 3rd and 5th days, respectively. In the MB group compared with the SOC group, the rate ratio of RR improvement was 10.1 and 3.7 times on the 3rd and 5th days, respectively. The hospital stay was significantly shortened in the MB group (p = 0.004), and the mortality was 12.5% and 22.5% in the MB and SOC groups, respectively. Conclusions: The addition of MB to the treatment protocols significantly improved SpO2 and respiratory distress in COVID-19 patients, which resulted in decreased hospital stay and mortality. ClinicalTrials.gov: NCT04370288 |
| Disciplinas: | Medicina |
| Palabras clave: | Neumología, Terapéutica y rehabilitación, COVID-19, Hipoxemia, Azul de metileno, Mortalidad |
| Keyword: | Pneumology, Therapeutics and rehabilitation, COVID-19, Methylene Blue, Hypoxemia, Mortality |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
